US Stock Insider Trading | Mineralys disclosed 2 insider transactions on February 11

K-LinePoet · 2026-02-24T05:57:48+00:00

Mineralys executive Rodman David Malcom recently conducted multiple insider transactions, including purchasing 2,171 shares and selling the same number of shares on February 9, 2026. Additionally, the company focuses on developing drugs to treat hypertension and related diseases.

K-LinePoet

2026-02-24 05:57:48

Abstract generation in progress

On February 11, 2026, Mineralys (MLYS) disclosed two insider trading transactions. Executive Rodman David Malcom purchased 2,171 shares on February 9, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 11, 2026	Executive	Rodman David Malcom	February 9, 2026	Buy	2,171	16.00	$34,700
February 11, 2026	Executive	Rodman David Malcom	February 9, 2026	Sell	2,171	30.21	$65,600
January 20, 2026	Executive	Rodman David Malcom	January 20, 2026	Sell	416	32.10	$13,400
January 20, 2026	Executive	Rodman David Malcom	January 20, 2026	Buy	416	15.44	$6,423.04
January 15, 2026	Executive	Rodman David Malcom	January 13, 2026	Buy	3,542	10.20	$36,100
January 15, 2026	Executive	Rodman David Malcom	January 13, 2026	Buy	4,167	14.25	$59,400
January 15, 2026	Executive	Rodman David Malcom	January 13, 2026	Sell	7,709	32.75	$252,500
January 15, 2026	Executive	Rodman David Malcom	January 14, 2026	Sell	11,400	32.61	$370,600
January 13, 2026	Executive	Rodman David Malcom	January 9, 2026	Sell	2,170	33.27	$72,200
January 13, 2026	Executive	Rodman David Malcom	January 12, 2026	Sell	6,348	32.32	$205,100

【Company Profile】

Mineralys Therapeutics, Inc., originally incorporated on May 31, 2019, is a Delaware-based company. It is a clinical-stage biopharmaceutical company focused on developing drugs to treat diseases caused by abnormally elevated aldosterone levels. The company’s lead candidate, Clorolone, is a proprietary oral highly selective aldosterone synthase inhibitor (ASI). It was initially developed to treat uncontrolled hypertension (uHTN), defined as individuals who, despite taking two or more antihypertensive medications or resistant hypertension (rHTN), still do not reach blood pressure below 130/80 mmHg. In the U.S., over 115 million patients suffer from persistent hypertension, with more than half failing to meet blood pressure targets, which are currently set at 130/80 mmHg with available medications. Over 30 million treated patients do not reach blood pressure goals, with about 20 million having systolic BP over 140 mmHg. Despite taking multiple medications, hypertensive patients remain at increased risk of cardiovascular disease or stroke, with mortality risks 1.8 and 2.5 times higher, respectively. In a Phase 2 clinical trial evaluating 200 subjects with uHTN and rHTN (target HTN), Clorolone administered once daily showed clinically and statistically significant blood pressure reductions and was well tolerated. Beyond hypertension, the company also plans to develop Clorolone for the treatment of chronic kidney disease (CKD).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.